Cambridge Investment Research Advisors’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CSCI Stock Details CSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3	Closed	-$8K	–	1601
2015 Q2	$8K	Buy	3 +1	+50%	+$4.21K	﹤0.01%	1437
2015 Q1	$11K	Buy	2 +1	+100%	+$5.73K	﹤0.01%	1403
2014 Q4	$6K	Hold	1	–	–	﹤0.01%	1361
2014 Q3	$13K	Hold	1	–	–	﹤0.01%	1454
2014 Q2	$12K	Hold	1	–	–	﹤0.01%	1333
2014 Q1	$12K	Hold	1	–	–	﹤0.01%	1289
2013 Q4	$14K	Sell	1 -7	-88%	-$93K	﹤0.01%	1230
2013 Q3	$120K	Buy	+8	New	+$127K	0.01%	1120

Other funds holding CSCI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return

Cambridge Investment Research Advisors's CSCI Position: Q3 2015 in Review

Cambridge Investment Research Advisors sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2015, closing a stake of 3 shares — an estimated $8K sold.

Cambridge Investment Research Advisors first reported a position in CSCI in Q3 2013 and held it in 8 quarters. The position peaked at $120K in Q3 2013. 16 funds tracked by Wall St. Rank hold CSCI as of Q3 2015.

Cambridge Investment Research Advisors reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
Cambridge Investment Research Advisors sold 3 COSCIENS Biopharma Inc. Common Stock shares in Q3 2015, an estimated $8K.
Cambridge Investment Research Advisors first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2013 and held it in 8 quarters.
Cambridge Investment Research Advisors's COSCIENS Biopharma Inc. Common Stock position peaked at $120K in Q3 2013.
16 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2015.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.